Logo

CombiMatrix Reports $5.8 Million in Q2 Cash Payments

Jul 01, 2003

NEW YORK, July 1 - CombiMatrix generated $5.8 million in cash payments for the second quarter, the company's parent, Acacia Research, said today.

 

CombiMatrix has a semiconductor-based microarray technology, which it is marketing and using to develop siRNA compounds that target common viral diseases.

 

The Squolamie, Wash., company did not specify the source of CombiMatrix's revenues, but CombiMatrix CEO Amit Kumar did mention the company's collaboration with Roche, its strategic alliance with Toppan, and the launch of the siRNA drug discovery program, Express Track.

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.